Phase Ia/Ib Basket Trial on the safety and efficacy of Mobocertinib in combination with T-DM1 for patients with HER2 mutant solid tumors Biomarker study (WJOG16022MTR)

Phase Ia/Ib Basket Trial on the safety and efficacy of Mobocertinib in combination with T-DM1 for patients with HER2 mutant solid tumors Biomarker study (WJOG16022MTR) - WJOG16022MTR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054805

Enrollment

Registered

2024-07-10

Start date

2024-08-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 mutant solid tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who were enrolled WJOG16022M Subjects must have a signed and dated written informed consent form for exploratory use of tissue/blood samples

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To evaluate exploratory biomarkers of mobocertinib in combination with T-DM1 for HER2 mutant solid tumors	—

Countries

Japan

Contacts

Public ContactNaoki Ishizuka

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results